about
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.Effect of ABO incompatibility on T-cell flow cytometry cross-match results prior to living donor kidney transplantation.Arterial stiffness assessed by digital volume pulse correlates with comorbidity in patients with ESRD.Pulse contour analysis: a valid assessment of central arterial stiffness in children?Rescue allocation and recipient oriented extended allocation in kidney transplantation-influence of the EUROTRANSPLANT allocation system on recipient selection and graft survival for initially nonaccepted organs.Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.The renal arterial resistance index and renal allograft survival.The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland.Reference values and factors associated with renal resistive index in a family-based population study.Meta-analyses qualify metzincins and related genes as acute rejection markers in renal transplant patients.The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.PTH and 1.25 vitamin D response to a low-calcium diet is associated with bone mineral density in renal stone formers.Living renal allograft transplantation: diffusion-weighted MR imaging in longitudinal follow-up of the donated and the remaining kidney.Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients.The assessment of biomarkers to detect nephrotoxicity using an integrated database.Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial.Comparison of physiological triggering schemes for diffusion-weighted magnetic resonance imaging in kidneys.Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study.Functional evaluation of transplanted kidneys with diffusion-weighted and BOLD MR imaging: initial experienceThe Reuse of Immunoadsorption Columns in ABO-Incompatible Kidney Transplantation Is EfficientArterial Stiffness Depends on Serum Ionized Calcium Levels During Dialysis With Regional Citrate AnticoagulationHeritability, determinants and reference values of renal length: a family-based population studySerum cytokine profile in patients with active lupus nephritisThree-year follow-up of human transplanted kidneys by diffusion-weighted MRI and blood oxygenation level-dependent imagingDonor Effect on Cortical Perfusion Intensity in Renal Allograft Recipients: A Paired Kidney AnalysisImpact of renal insufficiency on clinical outcomes in patients with critical limb ischemia undergoing endovascular revascularizationNeue Entwicklungen in der NierentransplantationFoxP3 Positive T Cells in Graft Biopsies From Living Donor Kidney Transplants After Donor-Specific TransfusionsEffect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidismFTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and AustralasiaMikroalbuminurie – ein neuer Marker für kardiovaskuläres Risiko?Protocol biopsy program after renal transplantation: structure and first resultsTreatment of chronic renal allograft failure by addition of mycophenolate mofetil: single-center experience in 40 patientsGemella morbillorum-spondylodiscitis in a patient with a renal graftSuccessful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipientsPrevalence of active hepatitis E virus infection and efficacy of ribavirin treatment in renal allograft recipients
P50
Q33394235-272A97A8-D369-4741-8F72-298089777F91Q39176690-DCE3CD0F-B583-41CC-A9EF-D1349B3790B5Q39766759-E32E2CD3-CC8D-45F7-A7BD-8E9008ABD116Q39826770-58D8F949-A66B-4653-9EAC-7C3385BA7424Q40175885-080143DA-6120-4E0E-9D8A-FDE20968B37CQ41673673-884A3D41-93AF-44E7-95AA-89842F598DE6Q43702596-21EC425E-8390-4282-B925-A4A2DA8B8EB2Q44145445-C60B1F50-0EE2-4E31-8E19-E6DFB471354CQ45241380-8A5CD335-A03F-40A8-A81D-C85AA8CEB8DAQ46479772-531DB848-A328-488C-97A3-3ACE0E1F8A8BQ46533193-FBD5D4F4-F9FD-4862-A3A5-699782D52C29Q46656803-2450C447-4359-45F7-BA09-3DC0083EE7F5Q46834869-C53F6C76-31EF-430D-B1BB-015B3B3B87BDQ47940086-C156665C-D527-4746-B263-F65A481387BFQ50926520-5255779A-8EED-4316-B7F6-2E6EA6F427C0Q51302246-7AA7F941-3A72-4C89-8B12-125DA87F661CQ51701033-76BC2207-EF2D-4E4D-9BEA-59F7CD789662Q54334382-318D0031-1639-42E0-B2A6-4C9809879136Q55515813-45B68C0A-31D7-41DC-822E-949E74F03F9BQ56786680-2D86C5B1-4D15-4934-8C5A-E7B346F5DED7Q63431621-376FD14E-6CF4-4FCC-9E18-9867502E3FD2Q63431622-9906A3CB-424E-4AC8-9766-BCFD2376954FQ63431623-B384934E-4CA9-4597-8A28-4266EBC276AEQ63431624-4E6EA3A4-344A-4BA5-AD40-7349E461AC6AQ63431625-5DBE22DA-EEB9-404D-BFAD-4A31092B4AB3Q63431626-20737C9A-DBB9-4F5F-B1C5-08B85B2131C3Q63431628-0BC34D3F-5E3D-4238-9045-B4174943FB30Q63431629-8DB9E865-E168-4FEA-AED4-C911075333B6Q63431632-DD5B66F8-0CDD-455E-BFC5-3274C9266627Q63431634-E8679FD1-38EA-4DA4-8ED2-B43B638B9751Q63431636-515C1FA5-2635-4FCE-8530-D474DD9EAABCQ63431637-F9E8DAB0-F9B5-4D7E-970B-6DACBDABE4E1Q63431638-AD472C03-1045-4FB3-92C0-6FD8F981B1EBQ63431639-8CD65F24-C4C8-4327-B984-34A420299252Q63431640-21C48B84-8CFF-47CC-B7C4-F5D0774B5E2EQ91887430-9EBBBA3C-2528-42F1-984F-5D58792B82C6Q92722821-41156916-B977-43AE-84B9-076038F165B0
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ute Eisenberger
@ast
Ute Eisenberger
@en
Ute Eisenberger
@es
Ute Eisenberger
@nl
Ute Eisenberger
@sl
type
label
Ute Eisenberger
@ast
Ute Eisenberger
@en
Ute Eisenberger
@es
Ute Eisenberger
@nl
Ute Eisenberger
@sl
prefLabel
Ute Eisenberger
@ast
Ute Eisenberger
@en
Ute Eisenberger
@es
Ute Eisenberger
@nl
Ute Eisenberger
@sl
P106
P1153
14068353100
P21
P31
P496
0000-0003-3862-6933